Investment case

ADARx Pharmaceuticals, Inc.

ADRX · 7 developments mapped · last assessed 2026-09-25

Market Ontology has mapped 7 macro, policy, and market developments to ADARx Pharmaceuticals, Inc. since 2026-09-25. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.

Last close

Unavailable

No published quote

Market cap

Unavailable

Equity value

Diluted shares

Unavailable

Latest reported

Sector

Unavailable

Listing

Unavailable

Filings

Unavailable

No published filing

Valuation

No validated run has been published for ADRX yet, so no modelled value is shown. The ADRX valuation is in the public catch-up queue.

Subscribers do not wait for the weekly cycle: they run ADRX on demand, against live prices and the latest filings, and change any assumption the developments below move.

Filed financials

A validated filed-statement snapshot has not been published for ADRX. Missing data is not estimated or replaced with scenario assumptions.

Continue this research

Value ADRX on your own assumptions

Run the valuation on ADARx Pharmaceuticals, Inc., change any assumption the events above move, and see the price that falls out.

Public valuations here are refreshed weekly and only published once a run passes every validation check. Subscribers run ADRX on demand instead, against live prices and the latest filings.

Subscribe to value any ticker

Opportunities created

Research workflows

Trade ADRX

Professional

Open trade discovery with ADARx Pharmaceuticals, Inc. and ADRX already in context.

Open

Find pricing gaps in ADRX

Institutional

Open relative-value and arbitrage analysis with ADRX already in context.

Open

Professional actions continue at $399/month. Institutional arbitrage requires the $399/month tier.

$399/month · charged today · cancel anytime. Opens ADRX first, then any listed company you want to value or monitor.

Choose another company

Current case

Strongest support
ADARx Pharmaceuticals prices upsized $446.3M initial public offering at $17 per share
Direct market entry and capital infusion. IPO pricing and initial trading performance.
2026-09-25 · Moves initial market capitalization, liquidity premium, cost of equity
Open question
ADARx Pharma Prices Upsized $446.3M IPO at $17 on Nasdaq
Direct market debut and initial trading dynamics; investor sentiment following IPO pricing and first day performance.
2026-09-25 · Moves initial market capitalization, investor perception of growth prospects

What changed, by assumption

Initial market capitalization

2026-09-25ADARx Pharmaceuticals prices upsized $446.3M initial public offering at $17 per share
2026-09-25ADARx Pharma Prices Upsized $446.3M IPO at $17 on Nasdaq

Initial public offering price

2026-09-25ADARx Pharmaceuticals Prices Upsized $446.3M Nasdaq IPO at $17 per Share

Market capitalization

2026-09-25ADARx Pharmaceuticals Prices Upsized $446.3M Initial Public Offering at $17

Probability of success for clinical trials

2026-09-25ADARx Pharmaceuticals prices upsized $446.3M IPO at $17 per share

Cash runway

2026-09-25ADARx Pharmaceuticals Prices Upsized $446.3M Nasdaq IPO at $17/Share

Event impact log

Full ledger →

Date	Mechanism	Direction	Horizon	Impact
2026-09-25	ADARx Pharmaceuticals prices upsized $446.3M initial public offering at $17 per share	Bullish	intraday	0.90
2026-09-25	ADARx Pharma Prices Upsized $446.3M IPO at $17 on Nasdaq	watch	intraday	0.90
2026-09-25	ADARx Pharmaceuticals Prices Upsized $446.3M Nasdaq IPO at $17 per Share	mixed	intraday	0.90
2026-09-25	ADARx Pharmaceuticals Prices Upsized $446.3M Nasdaq IPO at $17 per Share	Bullish	1-3m	0.80
2026-09-25	ADARx Pharmaceuticals Prices Upsized $446.3M Initial Public Offering at $17	mixed	intraday	0.90
2026-09-25	ADARx Pharmaceuticals prices upsized $446.3M IPO at $17 per share	mixed	1-5y	0.90
2026-09-25	ADARx Pharmaceuticals Prices Upsized $446.3M Nasdaq IPO at $17/Share	Bullish	1-5d	0.90

Value ADRX yourself$399/month

Continue this research

Value ADRX on your own assumptions

Run the valuation on ADARx Pharmaceuticals, Inc., change any assumption the events above move, and see the price that falls out.

Public valuations here are refreshed weekly and only published once a run passes every validation check. Subscribers run ADRX on demand instead, against live prices and the latest filings.

Subscribe to value any ticker

Opportunities created

Research workflows

Trade ADRX

Professional

Open trade discovery with ADARx Pharmaceuticals, Inc. and ADRX already in context.

Open

Find pricing gaps in ADRX

Institutional

Open relative-value and arbitrage analysis with ADRX already in context.

Open

Professional actions continue at $399/month. Institutional arbitrage requires the $399/month tier.

$399/month · charged today · cancel anytime. Opens ADRX first, then any listed company you want to value or monitor.

Choose another company

ADARx Pharmaceuticals, Inc.

ADRX · 7 developments mapped · last assessed 2026-09-25

Value ADRX on your own assumptions

Run the valuation on ADARx Pharmaceuticals, Inc., change any assumption the events above move, and see the price that falls out.

Public valuations here are refreshed weekly and only published once a run passes every validation check. Subscribers run ADRX on demand instead, against live prices and the latest filings.

Subscribe to value any ticker

Opportunities created

Research workflows

Trade ADRX

Professional

Open trade discovery with ADARx Pharmaceuticals, Inc. and ADRX already in context.

Open

Find pricing gaps in ADRX

Institutional

Open relative-value and arbitrage analysis with ADRX already in context.

Open

Professional actions continue at $399/month. Institutional arbitrage requires the $399/month tier.

$399/month · charged today · cancel anytime. Opens ADRX first, then any listed company you want to value or monitor.

Choose another company

Date

Mechanism

Direction

Horizon

Impact

2026-09-25

ADARx Pharmaceuticals prices upsized $446.3M initial public offering at $17 per share

Bullish

intraday

0.90

2026-09-25

ADARx Pharma Prices Upsized $446.3M IPO at $17 on Nasdaq

watch

intraday

0.90

2026-09-25

ADARx Pharmaceuticals Prices Upsized $446.3M Nasdaq IPO at $17 per Share

mixed

intraday

0.90

2026-09-25

ADARx Pharmaceuticals Prices Upsized $446.3M Nasdaq IPO at $17 per Share

Bullish

1-3m

0.80

2026-09-25

ADARx Pharmaceuticals Prices Upsized $446.3M Initial Public Offering at $17

mixed

intraday

0.90

2026-09-25

ADARx Pharmaceuticals prices upsized $446.3M IPO at $17 per share

mixed

1-5y

0.90

2026-09-25

ADARx Pharmaceuticals Prices Upsized $446.3M Nasdaq IPO at $17/Share

Bullish

1-5d

0.90

Value ADRX on your own assumptions

Run the valuation on ADARx Pharmaceuticals, Inc., change any assumption the events above move, and see the price that falls out.

Public valuations here are refreshed weekly and only published once a run passes every validation check. Subscribers run ADRX on demand instead, against live prices and the latest filings.

Subscribe to value any ticker

Opportunities created

Research workflows

Trade ADRX

Professional

Open trade discovery with ADARx Pharmaceuticals, Inc. and ADRX already in context.

Open

Find pricing gaps in ADRX

Institutional

Open relative-value and arbitrage analysis with ADRX already in context.

Open

Professional actions continue at $399/month. Institutional arbitrage requires the $399/month tier.

$399/month · charged today · cancel anytime. Opens ADRX first, then any listed company you want to value or monitor.

Choose another company